Chris H Takimoto
Overview
Explore the profile of Chris H Takimoto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
63
Citations
2672
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cottrell T, Lotze M, Ali A, Bifulco C, Capitini C, Chow L, et al.
J Immunother Cancer
. 2025 Mar;
13(3).
PMID: 40054999
Immunotherapy of cancer is now an essential pillar of treatment for patients with many individual tumor types. Novel immune targets and technical advances are driving a rapid exploration of new...
2.
3.
Chao M, Takimoto C, Feng D, McKenna K, Gip P, Liu J, et al.
Front Oncol
. 2020 Feb;
9:1380.
PMID: 32038992
In recent years, immunotherapies have been clinically investigated in AML and other myeloid malignancies. While most of these are focused on stimulating the adaptive immune system (including T cell checkpoint...
4.
George G, Barata P, Campbell A, Chen A, Cortes J, Hyman D, et al.
Cancer Treat Rev
. 2019 May;
76:33-40.
PMID: 31108240
Attribution of adverse events (AEs) is critical to oncology drug development and the regulatory process. However, processes for determining the causality of AEs are often sub-optimal, unreliable, and inefficient. Thus,...
5.
Sikic B, Lakhani N, Patnaik A, Shah S, Chandana S, Rasco D, et al.
J Clin Oncol
. 2019 Feb;
37(12):946-953.
PMID: 30811285
Purpose: To evaluate the safety, pharmacokinetics, and pharmacodynamics of Hu5F9-G4 (5F9), a humanized IgG4 antibody that targets CD47 to enable phagocytosis. Patients And Methods: Adult patients with solid tumors were...
6.
Advani R, Flinn I, Popplewell L, Forero A, Bartlett N, Ghosh N, et al.
N Engl J Med
. 2018 Nov;
379(18):1711-1721.
PMID: 30380386
Background: The Hu5F9-G4 (hereafter, 5F9) antibody is a macrophage immune checkpoint inhibitor blocking CD47 that induces tumor-cell phagocytosis. 5F9 synergizes with rituximab to eliminate B-cell non-Hodgkin's lymphoma cells by enhancing...
7.
Sankhala K, Takimoto C, Mita A, Xiong H, Rodon J, Mehrvarz Sarshekeh A, et al.
Invest New Drugs
. 2018 Apr;
37(1):76-86.
PMID: 29667134
Purpose DFP-10917 is a novel deoxycytidine analog with a unique mechanism of action. Brief exposure to high concentrations of DFP-10917 inhibits DNA polymerase resulting in S-phase arrest, while prolonged exposure...
8.
Nikanjam M, Stewart C, Takimoto C, Synold T, Beaty O, Fouladi M, et al.
Cancer Chemother Pharmacol
. 2015 Jan;
75(3):495-503.
PMID: 25557868
Purpose: To characterize the determinants of variability for oxaliplatin pharmacokinetics including age, renal function, and hepatic function in children and adults. Methods: Oxaliplatin pharmacokinetic data were combined from phase I...
9.
Baselga J, Mita A, Schoffski P, Dumez H, Rojo F, Tabernero J, et al.
Clin Cancer Res
. 2012 Sep;
18(22):6364-72.
PMID: 23014528
Purpose: In this first-in-human study of AEE788, a tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR), HER-2, and VEGFR-2, a comprehensive pharmacodynamic program was implemented in addition to the...
10.
LoRusso P, Venkatakrishnan K, Ramanathan R, Sarantopoulos J, Mulkerin D, Shibata S, et al.
Clin Cancer Res
. 2012 Mar;
18(10):2954-63.
PMID: 22394984
Purpose: The proteasome inhibitor bortezomib undergoes oxidative hepatic metabolism. This study (NCI-6432; NCT00091117) was conducted to evaluate bortezomib pharmacokinetics and safety in patients with varying degrees of hepatic impairment, to...